Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Tokyo University of Pharmacy and Life Sciences has 1 pending office action currently active within the Biotechnology & Pharmaceuticals technology area. This workload is handled by 1 distinct examiner and is situated within 1 distinct art unit. Such a concentrated profile indicates that the company's current patenting efforts are not spread across different examination groups, which simplifies the tracking of procedural requirements but increases reliance on a single examiner's interpretation of the prior art.
The busiest examiner for Tokyo University of Pharmacy and Life Sciences is COFFA, SERGIO, who is responsible for the 1 busiest examiner pending office action. With 1 distinct examiner managing the entire pending portfolio, the prosecution outcomes are tied directly to this individual's specific standards. Practitioners should note that the 1 distinct art unit involved provides a stable environment for prosecution, as the company is not currently navigating the varying internal policies of multiple USPTO divisions. This singular focus on 1 pending office action suggests an early-stage or highly specialized intellectual property strategy.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| COFFA, SERGIO | 1 | 61.1% | +32.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17442797 | CELL LAYER PERMEATION PROMOTER. COMPOSITION FOR FACILITATING DRUG ABSORPTION. AND PHARMACEUTICAL COMPOSITION | COFFA, SERGIO | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17442797 | CELL LAYER PERMEATION PROMOTER. COMPOSITION FOR FACILITATING DRUG ABSORPTION. AND PHARMACEUTICAL COMPOSITION | COFFA, SERGIO | 1658 | §103 | Final Rejection | — | Pending | Jan 27, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTokyo University of Pharmacy and Life Sciences has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Sergio Coffa has the most, with 1 of Tokyo University of Pharmacy and Life Sciences's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
